Treatment of Hepatic Encephalopathy

Initial Treatment of Overt Hepatic Encephalopathy

The American Association for the Study of Liver Diseases recommends identifying and treating precipitating factors for hepatic encephalopathy as the first priority in management, with lactulose as the first-choice treatment for episodic OHE, Grade II-1, B, 1 recommendation 1, 2, 3
Non-absorbable disaccharides, such as lactulose, are associated with significantly more frequent resolution of acute or chronic overt HE and reduction in mortality compared to placebo, with a reduction in blood ammonia levels 3

The American Association for the Study of Liver Diseases recommends lactulose for prevention of recurrent episodes of HE after the initial episode, Grade II-1, A, 1, and rifaximin as an add-on to lactulose for prevention of recurrent episodes of HE after the second episode, Grade I, A, 1 1, 2, 3, 4

Rifaximin added to lactulose is the best-documented agent to maintain remission in patients who have already experienced one or more bouts of OHE while on lactulose treatment, with a significant reduction in the risk of overt HE recurrence and HE-related hospitalization 1, 2

For patients who cannot tolerate lactulose, rifaximin alone may be considered, though this is based on expert opinion rather than strong evidence, according to the Liver International guidelines 3
Neither rifaximin nor lactulose has been shown to prevent post-TIPS HE better than placebo, so routine prophylactic therapy is not recommended in this specific situation, as stated by the American Association for the Study of Liver Diseases 1, 2

Rifaximin should not be used as monotherapy for initial treatment of overt HE, as evidence supports lactulose as first-line therapy, according to the Liver International guidelines 3
Long-term antibiotics like neomycin and metronidazole have significant side effects, making them unsuitable for continuous long-term use, as recommended by the American Association for the Study of Liver Diseases 1, 2
Simple laxatives alone do not have the prebiotic properties of disaccharides like lactulose and are not recommended, as stated by the American Association for the Study of Liver Diseases 1

The European Association for the Study of the Liver recommends identifying and treating precipitating factors first, as nearly 90% of patients can be managed by correcting these alone 5
Lactulose demonstrates significantly more frequent resolution of acute overt HE and reduction in mortality compared to placebo, with a Grade 1+ recommendation 5

The American Association for the Study of Liver Diseases suggests that either lactulose or rifaximin can be used to improve quality of life and reduce progression to overt HE, with a Grade 2+ recommendation 5, 6
Both agents significantly improve cognitive performance and neuropsychiatric testing in covert HE 5, 6
Rifaximin has fewer gastrointestinal side effects than lactulose, making it a reasonable choice based on tolerability 5

Rifaximin is a minimally absorbed antibiotic that modulates intestinal microbiota locally, with less than 0.4% systemic absorption 5